• Publications
  • Influence
Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors.
It is demonstrated that, for the purpose of anticancer therapy, bone marrow-derived mesenchymal stem cells (MSCs) can produce biological agents locally at tumor sites and that the tumor microenvironment preferentially promotes the engraftment of MSCs as compared with other tissues. Expand
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
It is concluded that purine analog-containing nonmyeloablative regimens allow engraftment of HLA-compatible hematopoietic progenitor cells and warrants further study in patients with leukemia who are ineligible for conventional transplantation with myeloablatives either because of age or concurrent medical conditions. Expand
Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study
These data support the use of HLA-matched and one- or two-antigen Hla-mismatched umbilical cord blood in children with acute leukaemia who need transplantation and greater investment in large-scale banking is needed to increase HLA diversity. Expand
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.
Fludarabine/melphalan combinations are feasible in older patients with associated comorbidities, and long-term disease control can be achieved with reduced-intensity conditioning in this population, according to multivariate analysis. Expand
Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.
Injected MSC-IFN-beta cells suppressed the growth of pulmonary metastases, presumably through the local production of IFN- beta in the tumor microenvironment, and may be an effective platform for the targeted delivery of therapeutic proteins to cancer sites. Expand
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
There was a strong correlation between the presence of PR1-specific T cells and clinical responses after IFN-α and allogeneic BMT, providing for the first time direct evidence of a role for T-cell immunity in clearing malignant cells. Expand
Outcomes after transplantation of cord Blood or bone marrow from unrelated donors in adults with leukemia
Transplanting HLA-matched bone marrow was associated with the lowest all-cause mortality and cord blood mismatching for 1 or 2 antigens and bone marrow mismatched for 1 antigen are acceptable alternatives. Expand
Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.
Zygomycosis should be considered in immunosuppressed patients who develop sinusitis while receiving VRC prophylaxis, especially those with diabetes and malnutrition. Expand
Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia.
HLA-mismatched cord blood should be considered an acceptable source of hematopoietic stem-cell grafts for adults in the absence of an HLA-matched adult donor. Expand
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
NK cells have therapeutic potential for a wide variety of human malignancies. However, because NK cells expand poorly in vitro, have limited life spans in vivo, and represent a small fraction ofExpand